These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 27375105)

  • 1. Progression-free survival with regorafenib in gastric cancer.
    Burki TK
    Lancet Oncol; 2016 Aug; 17(8):e323. PubMed ID: 27375105
    [No Abstract]   [Full Text] [Related]  

  • 2. Apatinib for the treatment of gastric cancer.
    Roviello G; Ravelli A; Fiaschi AI; Cappelletti MR; Gobbi A; Senti C; Zanotti L; Polom K; Reynolds AR; Fox SB; Generali D
    Expert Rev Gastroenterol Hepatol; 2016 Aug; 10(8):887-92. PubMed ID: 27376400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib.
    Papadimitriou M; Papadimitriou CA
    Anticancer Res; 2021 Feb; 41(2):567-582. PubMed ID: 33517262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial.
    Pavlakis N; Sjoquist KM; Martin AJ; Tsobanis E; Yip S; Kang YK; Bang YJ; Alcindor T; O'Callaghan CJ; Burnell MJ; Tebbutt NC; Rha SY; Lee J; Cho JY; Lipton LR; Wong M; Strickland A; Kim JW; Zalcberg JR; Simes J; Goldstein D
    J Clin Oncol; 2016 Aug; 34(23):2728-35. PubMed ID: 27325864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenvatinib improves survival in refractory thyroid cancer.
    Mayor S
    Lancet Oncol; 2015 Mar; 16(3):e110. PubMed ID: 25683848
    [No Abstract]   [Full Text] [Related]  

  • 6. Regorafenib for gastrointestinal malignancies : from preclinical data to clinical results of a novel multi-target inhibitor.
    Aprile G; Macerelli M; Giuliani F
    BioDrugs; 2013 Jun; 27(3):213-24. PubMed ID: 23435872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Mir O; Brodowicz T; Italiano A; Wallet J; Blay JY; Bertucci F; Chevreau C; Piperno-Neumann S; Bompas E; Salas S; Perrin C; Delcambre C; Liegl-Atzwanger B; Toulmonde M; Dumont S; Ray-Coquard I; Clisant S; Taieb S; Guillemet C; Rios M; Collard O; Bozec L; Cupissol D; Saada-Bouzid E; Lemaignan C; Eisterer W; Isambert N; Chaigneau L; Cesne AL; Penel N
    Lancet Oncol; 2016 Dec; 17(12):1732-1742. PubMed ID: 27751846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Angiogenesis in Colorectal Cancer: Tyrosine Kinase Inhibitors.
    Kircher SM; Nimeiri HS; Benson AB
    Cancer J; 2016; 22(3):182-9. PubMed ID: 27341596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma.
    Martin AJ; Gibbs E; Sjoquist K; Pavlakis N; Simes J; Price T; Shannon J; Gill S; Jain V; Liu G; Kannourakis G; Kim YH; Kim JW; Goldstein D;
    Gastric Cancer; 2018 May; 21(3):473-480. PubMed ID: 28815316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ramucirumab plus paclitaxel for gastric cancer in China.
    Yoon HH
    Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):975-976. PubMed ID: 34626551
    [No Abstract]   [Full Text] [Related]  

  • 11. Regorafenib: Dress.
    Prescrire Int; 2015 Jan; 24(156):20-1. PubMed ID: 25729832
    [No Abstract]   [Full Text] [Related]  

  • 12. [Multikinase inhibitor regorafenib offers an efficient therapeutic alternative].
    Rev Med Suisse; 2014 May; 10(431):1108. PubMed ID: 24941678
    [No Abstract]   [Full Text] [Related]  

  • 13. Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours.
    Shirley M; Keating GM
    Drugs; 2015 Jun; 75(9):1009-17. PubMed ID: 25998375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
    Rutkowski P; Stępniak J
    Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors.
    Myint ZW; Sen JM; Watts NL; Druzgal TJ; Nathan BR; Ward MD; Boyer JE; Fracasso PM
    Clin Colorectal Cancer; 2014 Jun; 13(2):127-30. PubMed ID: 24461491
    [No Abstract]   [Full Text] [Related]  

  • 16. Apatinib for the treatment of gastric cancer.
    Geng R; Li J
    Expert Opin Pharmacother; 2015 Jan; 16(1):117-22. PubMed ID: 25420417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regorafenib in gastrointestinal stromal tumors.
    Sirohi B; Philip DS; Shrikhande SV
    Future Oncol; 2014; 10(9):1581-7. PubMed ID: 25145429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenesis and apatinib: a new hope for patients with advanced gastric cancer?
    de Mello RA; de Oliveira J; Antoniou G
    Future Oncol; 2017 Feb; 13(4):295-298. PubMed ID: 27928929
    [No Abstract]   [Full Text] [Related]  

  • 19. Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer.
    Huynh H; Ong R; Zopf D
    J Exp Clin Cancer Res; 2015 Oct; 34():132. PubMed ID: 26514182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
    Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
    Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.